{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:00:31Z","timestamp":1783612831036,"version":"3.55.0"},"reference-count":186,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32000517"],"award-info":[{"award-number":["32000517"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82025027"],"award-info":[{"award-number":["82025027"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82150115"],"award-info":[{"award-number":["82150115"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2021T14016"],"award-info":[{"award-number":["2021T14016"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003472","name":"Harbin Institute of Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003472","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA1105200"],"award-info":[{"award-number":["2022YFA1105200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.canlet.2023.216318","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T21:12:23Z","timestamp":1689369143000},"page":"216318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"special_numbering":"C","title":["The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells"],"prefix":"10.1016","volume":"569","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9463-9363","authenticated-orcid":false,"given":"Qingyu","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2469-5604","authenticated-orcid":false,"given":"Ying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2023.216318_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215798","article-title":"LncRNAs in tumor metabolic reprogramming and immune microenvironment remodeling","volume":"543","author":"Yang","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2023.216318_bib2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.canlet.2023.216318_bib3","first-page":"311","article-title":"Targeted therapies: a new generation of cancer treatments","volume":"77","author":"Gerber","year":"2008","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.canlet.2023.216318_bib4","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2023.216318_bib5","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.ctrv.2014.05.003","article-title":"Toxicity of targeted therapy: implications for response and impact of genetic polymorphisms","volume":"40","author":"Liu","year":"2014","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.canlet.2023.216318_bib6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1186\/s40880-015-0047-1","article-title":"Targeted therapy: resistance and re-sensitization","volume":"34","author":"Chen","year":"2015","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.canlet.2023.216318_bib7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cell.2020.03.001","article-title":"The emerging landscape of immune cell therapies","volume":"181","author":"Weber","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2023.216318_bib8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.canlet.2021.04.021","article-title":"Emerging immune checkpoints in the tumor microenvironment: implications for cancer immunotherapy","volume":"511","author":"Wei","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2023.216318_bib9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2023.216318_bib10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2023.216318_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215816","article-title":"Colorectal cancer immunotherapy-Recent progress and future directions","volume":"545","author":"Zhao","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2023.216318_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2023.216318_bib13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrd4591","article-title":"Combination cancer immunotherapy and new immunomodulatory targets, Nature reviews","volume":"14","author":"Mahoney","year":"2015","journal-title":"Drug discovery"},{"key":"10.1016\/j.canlet.2023.216318_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2021.10.044","article-title":"Intratumoral xenogeneic tissue-specific cell immunotherapy inhibits tumor growth by increasing antitumor immunity in murine triple negative breast and pancreatic tumor models","volume":"545","author":"Huang","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2023.216318_bib15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.canlet.2023.216318_bib16","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","article-title":"Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2023.216318_bib17","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2023.216318_bib18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2023.216318_bib19","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2023.216318_bib20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2023.216318_bib21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"Journal for immunotherapy of cancer"},{"key":"10.1016\/j.canlet.2023.216318_bib22","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann. Oncol. : official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.canlet.2023.216318_bib23","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.cell.2021.02.011","article-title":"Understanding and treating the inflammatory adverse events of cancer immunotherapy","volume":"184","author":"Dougan","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2023.216318_bib24","first-page":"9","article-title":"Treating with checkpoint inhibitors-figure $1 million per patient","volume":"8","author":"Andrews","year":"2015","journal-title":"American health & drug benefits"},{"key":"10.1016\/j.canlet.2023.216318_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2023.216318_bib26","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.canlet.2017.11.014","article-title":"Progress and challenges of predictive biomarkers of anti PD-1\/PD-L1 immunotherapy: a systematic review","volume":"414","author":"Teng","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2023.216318_bib27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2023.216318_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.canlet.2022.01.027","article-title":"HIF-1\u03b1 inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer","volume":"531","author":"Luo","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2023.216318_bib29","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jtho.2015.09.010","article-title":"PD-L1 is upregulated by simultaneous amplification of the PD-L1 and JAK2 genes in non-small cell lung cancer","volume":"11","author":"Ikeda","year":"2016","journal-title":"J. Thorac. Oncol. : official publication of the International Association for the Study of Lung Cancer"},{"key":"10.1016\/j.canlet.2023.216318_bib30","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2023.216318_bib31","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1038\/s41598-020-60437-0","article-title":"Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics","volume":"10","author":"Refae","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2023.216318_bib32","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2023.216318_bib33","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2023.216318_bib34","first-page":"1283","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial, the Lancet","volume":"17","author":"Younes","year":"2016","journal-title":"Oncology"},{"key":"10.1016\/j.canlet.2023.216318_bib35","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.canlet.2023.216318_bib36","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2023.216318_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215587","article-title":"ARID1A loss-of-function induces CpG island methylator phenotype","volume":"532","author":"Yamada","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2023.216318_bib38","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.canlet.2021.12.028","article-title":"Proteolysis of a histone acetyl reader, ATAD2, induces chemoresistance of cancer cells under severe hypoxia by inhibiting cell cycle progression in S phase","volume":"528","author":"Haitani","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2023.216318_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020462","article-title":"Decitabine augments chemotherapy-induced PD-L1 upregulation for PD-L1 blockade in colorectal cancer","volume":"12","author":"Huang","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2023.216318_bib40","doi-asserted-by":"crossref","first-page":"74036","DOI":"10.18632\/oncotarget.18198","article-title":"Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer","volume":"8","author":"Ch\u00fceh","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2023.216318_bib41","first-page":"750","volume":"vol. 23","author":"Hua","year":"2021"},{"key":"10.1016\/j.canlet.2023.216318_bib42","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1016\/j.celrep.2016.08.032","article-title":"BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression","volume":"16","author":"Zhu","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2023.216318_bib43","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.celrep.2017.02.011","article-title":"BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1","volume":"18","author":"Hogg","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2023.216318_bib44","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-15-0077-T","article-title":"HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade","volume":"3","author":"Woods","year":"2015","journal-title":"Cancer immunology research"},{"key":"10.1016\/j.canlet.2023.216318_bib45","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw283","article-title":"The MLL1-H3K4me3 axis-mediated PD-L1 expression and pancreatic cancer immune evasion","volume":"109","author":"Lu","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2023.216318_bib46","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.athoracsur.2018.08.056","article-title":"A positive correlation between the EZH2 and PD-L1 expression in resected lung adenocarcinomas","volume":"107","author":"Toyokawa","year":"2019","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.canlet.2023.216318_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115460","article-title":"The role of m6A-mediated PD-1\/PD-L1 in antitumor immunity","volume":"210","author":"Liu","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2023.216318_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.976107","article-title":"Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer","volume":"13","author":"Ji","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2023.216318_bib49","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.2147\/IJGM.S351815","article-title":"N6-Methyladenine-Related signature for immune microenvironment and response to immunotherapy in hepatocellular carcinoma","volume":"15","author":"Ren","year":"2022","journal-title":"Int. J. Gen. Med."},{"key":"10.1016\/j.canlet.2023.216318_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/jgo-21-686","article-title":"Estimating the prognosis of esophageal squamous cell carcinoma based on the Cancer Genome Atlas (TCGA) of m6A methylation-associated genes","volume":"13","author":"Pu","year":"2022","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.canlet.2023.216318_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1004212","article-title":"LncRNA MALAT1 regulates METTL3-mediated PD-L1 expression and immune infiltrates in pancreatic cancer","volume":"12","author":"Song","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2023.216318_bib52","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbrc.2020.06.153","article-title":"RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells","volume":"530","author":"Tsuruta","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2023.216318_bib53","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1158\/0008-5472.CAN-21-0468","article-title":"M(6)A demethylase ALKBH5 regulates PD-L1 expression and tumor immunoenvironment in intrahepatic cholangiocarcinoma","volume":"81","author":"Qiu","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2023.216318_bib54","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1962656","article-title":"YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer","volume":"10","author":"Tsuchiya","year":"2021","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2023.216318_bib55","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1021\/acscentsci.2c00107","article-title":"Allosteric regulation of IGF2BP1 as a novel strategy for the activation of tumor immune microenvironment","volume":"8","author":"Liu","year":"2022","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.canlet.2023.216318_bib56","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/s41467-018-03513-4","article-title":"RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia","volume":"9","author":"Cheng","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2023.216318_bib57","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41392-023-01395-7","article-title":"ALYREF mediates RNA m(5)C modification to promote hepatocellular carcinoma progression","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2023.216318_bib58","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-16-0224","article-title":"Dual faces of IFN\u03b3 in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity","volume":"22","author":"Mandai","year":"2016","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.canlet.2023.216318_bib59","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2023.216318_bib60","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.178.5.2623","article-title":"The JAK-STAT signaling pathway: input and output integration","volume":"178","author":"Murray","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2023.216318_bib61","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.febslet.2005.12.093","article-title":"Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274)","volume":"580","author":"Lee","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.canlet.2023.216318_bib62","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.aae0477","article-title":"Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity","volume":"353","author":"Dorand","year":"2016","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.canlet.2023.216318_bib63","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jneuroim.2004.06.013","article-title":"Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis","volume":"155","author":"Schreiner","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.canlet.2023.216318_bib64","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s10147-017-1161-7","article-title":"PD-L1 induced by IFN-\u03b3 from tumor-associated macrophages via the JAK\/STAT3 and PI3K\/AKT signaling pathways promoted progression of lung cancer","volume":"22","author":"Zhang","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2023.216318_bib65","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/s41388-021-02133-5","article-title":"Tumor-associated macrophages promote PD-L1 expression in tumor cells by regulating PKM2 nuclear translocation in pancreatic ductal adenocarcinoma","volume":"41","author":"Xia","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2023.216318_bib66","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12865-020-00396-3","article-title":"CXCL9 secreted by tumor-associated dendritic cells up-regulates PD-L1 expression in bladder cancer cells by activating the CXCR3 signaling","volume":"22","author":"Xiu","year":"2021","journal-title":"BMC Immunol."},{"key":"10.1016\/j.canlet.2023.216318_bib67","series-title":"Activated Fibroblasts Induce Immune Escape of TSCC through CCL25\/AKT Pathway","author":"Li","year":"2022"},{"key":"10.1016\/j.canlet.2023.216318_bib68","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.jhep.2019.08.034","article-title":"IL-17A secreted from lymphatic endothelial cells promotes tumorigenesis by upregulation of PD-L1 in hepatoma stem cells","volume":"71","author":"Wei","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2023.216318_bib69","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1172\/JCI126022","article-title":"IL-6\/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion","volume":"129","author":"Chan","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2023.216318_bib70","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3892\/ijo.2016.3632","article-title":"The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6\/JAK\/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer","volume":"49","author":"Zhang","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2023.216318_bib71","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1158\/0008-5472.CAN-14-3016","article-title":"IL10 and PD-1 cooperate to limit the activity of tumor-specific CD8+ T cells","volume":"75","author":"Sun","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2023.216318_bib72","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s40425-019-0770-2","article-title":"Mechanisms regulating PD-L1 expression on tumor and immune cells","volume":"7","author":"Chen","year":"2019","journal-title":"Journal for immunotherapy of cancer"},{"key":"10.1016\/j.canlet.2023.216318_bib73","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1189\/jlb.1209788","article-title":"IL-27 renders DC immunosuppressive by induction of B7-H1","volume":"89","author":"Karakhanova","year":"2011","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.canlet.2023.216318_bib74","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41392-020-00312-6","article-title":"Targeting NF-\u03baB pathway for the therapy of diseases: mechanism and clinical study","volume":"5","author":"Yu","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2023.216318_bib75","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","article-title":"PD-L1 is upregulated by EBV-driven LMP1 through NF-\u03baB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma","volume":"9","author":"Bi","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2023.216318_bib76","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1158\/0008-5472.CAN-14-3098","article-title":"Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-\u03bab to foster an immunosuppressive tumor microenvironment in ovarian cancer","volume":"75","author":"Peng","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2023.216318_bib77","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1038\/onc.2017.47","article-title":"MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer","volume":"36","author":"Bouillez","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2023.216318_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123410","article-title":"Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-\u03baB","volume":"10","author":"Gowrishankar","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2023.216318_bib79","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/leu.2017.103","article-title":"PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma","volume":"31","author":"Atsaves","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2023.216318_bib80","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.aac9935","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.canlet.2023.216318_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103756","article-title":"Therapeutic targeting of \"undruggable\" MYC","volume":"75","author":"Llombart","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.canlet.2023.216318_bib82","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2010.10.002","article-title":"CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation","volume":"18","author":"Rakhra","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2023.216318_bib83","doi-asserted-by":"crossref","first-page":"6235","DOI":"10.1038\/onc.2017.217","article-title":"BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR\/MAPK signaling pathways in non-small cell lung cancer","volume":"36","author":"Wang","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2023.216318_bib84","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.lungcan.2017.06.006","article-title":"MYC expression correlates with PD-L1 expression in non-small cell lung cancer","volume":"110","author":"Kim","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canlet.2023.216318_bib85","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.trecan.2019.08.005","article-title":"DUBs, hypoxia, and cancer","volume":"5","author":"Mennerich","year":"2019","journal-title":"Trends in cancer"},{"key":"10.1016\/j.canlet.2023.216318_bib86","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1172\/JCI137552","article-title":"HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer","volume":"130","author":"de Heer","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2023.216318_bib87","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.canlet.2022.01.012","article-title":"Engineering nanomedicines to inhibit hypoxia-inducible Factor-1 for cancer therapy","volume":"530","author":"Zhang","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2023.216318_bib88","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1158\/0008-5472.CAN-13-0992","article-title":"A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells","volume":"74","author":"Barsoum","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2023.216318_bib89","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2023.216318_bib90","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1718197115","article-title":"Chemotherapy induces enrichment of CD47(+)\/CD73(+)\/PDL1(+) immune evasive triple-negative breast cancer cells","volume":"115","author":"Samanta","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2023.216318_bib91","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1108514","article-title":"EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1\u03b1 and STAT3","volume":"5","author":"Koh","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2023.216318_bib92","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/2159-8290.CD-18-1321","article-title":"Targeting alterations in the RAF-MEK pathway","volume":"9","author":"Yaeger","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2023.216318_bib93","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nrc1503","article-title":"Targeting the mitogen-activated protein kinase cascade to treat cancer","volume":"4","author":"Sebolt-Leopold","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2023.216318_bib94","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1158\/1078-0432.CCR-13-2797","article-title":"Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma","volume":"20","author":"Atefi","year":"2014","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.canlet.2023.216318_bib95","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1128\/MCB.19.10.7138","article-title":"Interacting regions in Stat3 and c-Jun that participate in cooperative transcriptional activation","volume":"19","author":"Zhang","year":"1999","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2023.216318_bib96","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1078-0432.CCR-12-2731","article-title":"The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition","volume":"19","author":"Jiang","year":"2013","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.canlet.2023.216318_bib97","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/eji.200939289","article-title":"ERK\/p38 MAP-kinases and PI3K are involved in the differential regulation of B7-H1 expression in DC subsets","volume":"40","author":"Karakhanova","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.canlet.2023.216318_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215867","article-title":"FGFR1\/MAPK-directed brachyury activation drives PD-L1-mediated immune evasion to promote lung cancer progression","volume":"547","author":"Hu","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2023.216318_bib99","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2174\/0929867324666170227114356","article-title":"Emerging insight into MAPK inhibitors and immunotherapy in colorectal cancer","volume":"24","author":"Pancione","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.canlet.2023.216318_bib100","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.tcb.2013.11.002","article-title":"EGF receptor trafficking: consequences for signaling and cancer","volume":"24","author":"Tomas","year":"2014","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.canlet.2023.216318_bib101","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.canlet.2022.01.030","article-title":"Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt\/\u03b2-Catenin activity and cancer stemness","volume":"531","author":"Yan","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2023.216318_bib102","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/nm.3388","article-title":"The quest to overcome resistance to EGFR-targeted therapies in cancer","volume":"19","author":"Chong","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2023.216318_bib103","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","article-title":"Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer","volume":"76","author":"Lastwika","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2023.216318_bib104","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2023.216318_bib105","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1158\/0008-5472.CAN-15-2001","article-title":"Identification of the cell-intrinsic and -extrinsic pathways downstream of EGFR and IFN\u03b3 that induce PD-L1 expression in head and neck cancer","volume":"76","author":"Concha-Benavente","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2023.216318_bib106","article-title":"Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity","volume":"7","author":"Li","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2023.216318_bib107","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bbrc.2015.05.030","article-title":"EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-\u03baB","volume":"463","author":"Lin","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2023.216318_bib108","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.canlet.2021.08.008","article-title":"RNF144A deficiency promotes PD-L1 protein stabilization and carcinogen-induced bladder tumorigenesis","volume":"520","author":"Ho","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2023.216318_bib109","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2023.216318_bib110","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nm1517","article-title":"Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma","volume":"13","author":"Parsa","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2023.216318_bib111","article-title":"PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer","volume":"8","author":"Song","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2023.216318_bib112","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer immunology research"},{"key":"10.1016\/j.canlet.2023.216318_bib113","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41392-022-01191-9","article-title":"The Hippo signalling pathway and its implications in human health and diseases","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2023.216318_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215589","article-title":"YAP derived circ-LECRC functions as a \"brake signal\" to suppress hyperactivation of oncogenic YAP signalling in colorectal cancer","volume":"532","author":"An","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2023.216318_bib115","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.canlet.2021.12.016","article-title":"Hippo\/YAP signaling choreographs the tumor immune microenvironment to promote triple negative breast cancer progression via TAZ\/IL-34 axis","volume":"527","author":"Wang","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2023.216318_bib116","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/0008-5472.CAN-17-3139","article-title":"The Hippo pathway component TAZ promotes immune evasion in human cancer through PD-L1","volume":"78","author":"Janse van Rensburg","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2023.216318_bib117","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.cell.2016.11.005","article-title":"The Hippo pathway kinases LATS1\/2 suppress cancer immunity","volume":"167","author":"Moroishi","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2023.216318_bib118","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1158\/2326-6066.CIR-17-0320","article-title":"YAP-induced PD-L1 expression drives immune evasion in BRAFi-resistant melanoma","volume":"6","author":"Kim","year":"2018","journal-title":"Cancer immunology research"},{"key":"10.1016\/j.canlet.2023.216318_bib119","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12943-018-0810-4","article-title":"The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)","volume":"17","author":"Golding","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2023.216318_bib120","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1158\/1078-0432.CCR-10-1591","article-title":"Targeting anaplastic lymphoma kinase in lung cancer","volume":"17","author":"Shaw","year":"2011","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.canlet.2023.216318_bib121","doi-asserted-by":"crossref","first-page":"20852","DOI":"10.1073\/pnas.0810958105","article-title":"Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)","volume":"105","author":"Marzec","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2023.216318_bib122","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-0016","article-title":"Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer","volume":"21","author":"Ota","year":"2015","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.canlet.2023.216318_bib123","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2023.216318_bib124","first-page":"21","article-title":"Regulation of microRNA function in animals, Nature reviews","volume":"20","author":"Gebert","year":"2019","journal-title":"Molecular cell biology"},{"key":"10.1016\/j.canlet.2023.216318_bib125","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.4049\/jimmunol.182.3.1325","article-title":"MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes","volume":"182","author":"Gong","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2023.216318_bib126","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.cellsig.2014.12.003","article-title":"Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia","volume":"27","author":"Wang","year":"2015","journal-title":"Cell. Signal."},{"key":"10.1016\/j.canlet.2023.216318_bib127","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1038\/ncomms6241","article-title":"Metastasis is regulated via microRNA-200\/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression","volume":"5","author":"Chen","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2023.216318_bib128","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv303","article-title":"PDL1 Regulation by p53 via miR-34","volume":"108","author":"Cortez","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2023.216318_bib129","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1038\/leu.2017.163","article-title":"MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs","volume":"31","author":"Pyzer","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2023.216318_bib130","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00439-013-1275-6","article-title":"A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma","volume":"132","author":"Wang","year":"2013","journal-title":"Hum. Genet."},{"key":"10.1016\/j.canlet.2023.216318_bib131","doi-asserted-by":"crossref","first-page":"28125","DOI":"10.18632\/oncotarget.15924","article-title":"MicroRNA-152 regulates immune response via targeting B7-H1 in gastric carcinoma","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2023.216318_bib132","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.canlet.2021.05.037","article-title":"miR-105-5p regulates PD-L1 expression and tumor immunogenicity in gastric cancer","volume":"518","author":"Miliotis","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2023.216318_bib133","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11406","article-title":"miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint","volume":"7","author":"Xu","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2023.216318_bib134","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.bbrc.2017.05.074","article-title":"miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity","volume":"488","author":"Jia","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2023.216318_bib135","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jtho.2017.05.024","article-title":"Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma","volume":"12","author":"Kao","year":"2017","journal-title":"J. Thorac. Oncol. : official publication of the International Association for the Study of Lung Cancer"},{"key":"10.1016\/j.canlet.2023.216318_bib136","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/annonc\/mdt412","article-title":"Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma","volume":"24","author":"Reid","year":"2013","journal-title":"Ann. Oncol. : official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.canlet.2023.216318_bib137","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1128\/MCB.15.4.2219","article-title":"The nonamer UUAUUUAUU is the key AU-rich sequence motif that mediates mRNA degradation","volume":"15","author":"Zubiaga","year":"1995","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2023.216318_bib138","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1101\/gad.1282305","article-title":"Recruitment and activation of mRNA decay enzymes by two ARE-mediated decay activation domains in the proteins TTP and BRF-1","volume":"19","author":"Lykke-Andersen","year":"2005","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2023.216318_bib139","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","article-title":"Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA","volume":"47","author":"Coelho","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2023.216318_bib140","doi-asserted-by":"crossref","first-page":"11269","DOI":"10.1073\/pnas.0400541101","article-title":"Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells","volume":"101","author":"Vattem","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2023.216318_bib141","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.cell.2009.01.042","article-title":"Regulation of translation initiation in eukaryotes: mechanisms and biological targets","volume":"136","author":"Sonenberg","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2023.216318_bib142","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s43018-020-0056-0","article-title":"eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer","volume":"1","author":"Suresh","year":"2020","journal-title":"Nature cancer"},{"key":"10.1016\/j.canlet.2023.216318_bib143","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1042\/BCJ20200697","article-title":"eEF2K enhances expression of PD-L1 by promoting the translation of its mRNA","volume":"477","author":"Wu","year":"2020","journal-title":"Biochem. J."},{"key":"10.1016\/j.canlet.2023.216318_bib144","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41591-018-0321-2","article-title":"Translation control of the immune checkpoint in cancer and its therapeutic targeting","volume":"25","author":"Xu","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2023.216318_bib145","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162951","article-title":"Long noncoding RNA HITT coordinates with RGS2 to inhibit PD-L1 translation in T cell immunity","volume":"133","author":"Lin","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2023.216318_bib146","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.1158\/0008-5472.CAN-18-1892","article-title":"Posttranslational modifications of PD-L1 and their applications in cancer therapy","volume":"78","author":"Hsu","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2023.216318_bib147","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.immuni.2016.06.020","article-title":"Post-translational modification control of innate immunity","volume":"45","author":"Liu","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2023.216318_bib148","first-page":"265","article-title":"Protein degraders enter the clinic - a new approach to cancer therapy, Nature reviews","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.canlet.2023.216318_bib149","first-page":"277","article-title":"Functional characterization of Anaphase Promoting Complex\/Cyclosome (APC\/C) E3 ubiquitin ligases in tumorigenesis","volume":"1845","author":"Zhang","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2023.216318_bib150","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1146\/annurev-biochem-061516-044916","article-title":"Mechanisms of deubiquitinase specificity and regulation","volume":"86","author":"Mevissen","year":"2017","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.canlet.2023.216318_bib151","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.molcel.2018.07.030","article-title":"Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1","volume":"71","author":"Cha","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2023.216318_bib152","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature23643","article-title":"CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity","volume":"549","author":"Burr","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2023.216318_bib153","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature23669","article-title":"Identification of CMTM6 and CMTM4 as PD-L1 protein regulators","volume":"549","author":"Mezzadra","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2023.216318_bib154","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ccell.2016.10.010","article-title":"Deubiquitination and stabilization of PD-L1 by CSN5","volume":"30","author":"Lim","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2023.216318_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215902","article-title":"Glycosylation of immunoglobin G in tumors: function, regulation and clinical implications","volume":"549","author":"Yang","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2023.216318_bib156","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","article-title":"Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1","volume":"33","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2023.216318_bib157","doi-asserted-by":"crossref","first-page":"68291","DOI":"10.18632\/oncotarget.19309","article-title":"A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma","volume":"8","author":"D'Arrigo","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2023.216318_bib158","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1158\/1541-7786.MCR-17-0166","article-title":"Small-molecule Sigma1 modulator induces autophagic degradation of PD-L1","volume":"16","author":"Maher","year":"2018","journal-title":"Mol. Cancer Res. : MCR"},{"key":"10.1016\/j.canlet.2023.216318_bib159","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201846666","article-title":"Protein palmitoylation and cancer","volume":"19","author":"Ko","year":"2018","journal-title":"EMBO Rep."},{"key":"10.1016\/j.canlet.2023.216318_bib160","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41551-019-0375-6","article-title":"Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours","volume":"3","author":"Yao","year":"2019","journal-title":"Nature biomedical engineering"},{"key":"10.1016\/j.canlet.2023.216318_bib161","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41422-018-0124-5","article-title":"Palmitoylation stabilizes PD-L1 to promote breast tumor growth","volume":"29","author":"Yang","year":"2019","journal-title":"Cell Res."},{"key":"10.1016\/j.canlet.2023.216318_bib162","article-title":"Dihydropyridine calcium channel blockers suppress the transcription of PD-L1 by inhibiting the activation of STAT1","volume":"11","author":"Pan","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2023.216318_bib163","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/s41388-020-01592-6","article-title":"Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity","volume":"40","author":"Li","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2023.216318_bib164","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s40425-019-0733-7","article-title":"Niclosamide, an antihelmintic drug, enhances efficacy of PD-1\/PD-L1 immune checkpoint blockade in non-small cell lung cancer","volume":"7","author":"Luo","year":"2019","journal-title":"Journal for immunotherapy of cancer"},{"key":"10.1016\/j.canlet.2023.216318_bib165","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s13046-019-1303-z","article-title":"Flubendazole demonstrates valid antitumor effects by inhibiting STAT3 and activating autophagy","volume":"38","author":"Lin","year":"2019","journal-title":"J. Exp. Clin. Cancer Res. : CRN"},{"key":"10.1016\/j.canlet.2023.216318_bib166","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1038\/s41388-021-01897-0","article-title":"Dexamethasone suppresses immune evasion by inducing GR\/STAT3 mediated downregulation of PD-L1 and Ido1 pathways","volume":"40","author":"Xiang","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2023.216318_bib167","article-title":"Repositioning fenofibrate to reactivate p53 and reprogram the tumor-immune microenvironment in HPV+ head and neck squamous cell carcinoma","volume":"14","author":"O'Neill","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2023.216318_bib168","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215780","article-title":"Combination treatment with 17\u03b2-estradiol and anti-PD-L1 suppresses MC38 tumor growth by reducing PD-L1 expression and enhancing M1 macrophage population in MC38 colon tumor model","volume":"543","author":"Song","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2023.216318_bib169","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003819","article-title":"Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation","volume":"10","author":"Zhu","year":"2022","journal-title":"Journal for immunotherapy of cancer"},{"key":"10.1016\/j.canlet.2023.216318_bib170","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/10799893.2020.1839765","article-title":"Liothyronine could block the programmed death-ligand 1 (PDL1) activity: an e-Pharmacophore modeling and virtual screening study","volume":"42","author":"Pourzardosht","year":"2022","journal-title":"J. Recept. Signal Transduct. Res."},{"key":"10.1016\/j.canlet.2023.216318_bib171","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.canlet.2021.06.028","article-title":"PET\/CT metabolic patterns in systemic immune activation: a new perspective on the assessment of immunotherapy response and efficacy","volume":"520","author":"Jin","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2023.216318_bib172","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdv489","article-title":"Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies","volume":"27","author":"Ilie","year":"2016","journal-title":"Ann. Oncol. : official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.canlet.2023.216318_bib173","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2023.216318_bib174","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2023.216318_bib175","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2023.216318_bib176","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2023.216318_bib177","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.canlet.2023.216318_bib178","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.canlet.2023.216318_bib179","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","article-title":"Coinhibitory pathways in immunotherapy for cancer","volume":"34","author":"Baumeister","year":"2016","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.canlet.2023.216318_bib180","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.canlet.2023.216318_bib181","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1016\/j.cell.2021.07.020","article-title":"Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy","volume":"184","author":"Koikawa","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2023.216318_bib182","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41556-019-0373-7","article-title":"Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms","volume":"21","author":"Kim","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2023.216318_bib183","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2023.216318_bib184","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"Journal for immunotherapy of cancer"},{"key":"10.1016\/j.canlet.2023.216318_bib185","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.canlet.2023.216318_bib186","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science (New York, N.Y.)"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383523002690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383523002690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:10:06Z","timestamp":1759594206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383523002690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":186,"alternative-id":["S0304383523002690"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216318","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216318","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"216318"}}